vigabatrin has been researched along with Cocaine Abuse in 15 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the ocular safety of short-term vigabatrin treatment of cocaine abuse." | 9.16 | Visual field and ocular safety during short-term vigabatrin treatment in cocaine abusers. ( Berezina, TL; Fechtner, RD; Khouri, AS; Winship, MD, 2012) |
| "In this short-term pilot study, vigabatrin seemed to help treat cocaine and/or methamphetamine abuse." | 9.12 | Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin: ocular safety pilot results. ( Brodie, JD; Dewey, SL; Fechtner, RD; Federico, M; Figueroa, E; Khouri, AS; Ramirez, M, 2006) |
| "To evaluate the ocular safety of short-term vigabatrin treatment of cocaine abuse." | 5.16 | Visual field and ocular safety during short-term vigabatrin treatment in cocaine abusers. ( Berezina, TL; Fechtner, RD; Khouri, AS; Winship, MD, 2012) |
| "In this short-term pilot study, vigabatrin seemed to help treat cocaine and/or methamphetamine abuse." | 5.12 | Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin: ocular safety pilot results. ( Brodie, JD; Dewey, SL; Fechtner, RD; Federico, M; Figueroa, E; Khouri, AS; Ramirez, M, 2006) |
| "Cocaine dependence is a significant public health problem, yet no validated pharmacological treatment exists." | 2.78 | A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence. ( Bickel, WK; Ciraulo, DA; Galloway, GP; Gorodetzky, CW; Jasinski, D; Lewis, D; Miller, SR; Roache, JD; Segal, SD; Sheehan, M; Somoza, EC; Somoza, P; Watson, DW; Winhusen, T; Winship, D, 2013) |
| "Cocaine dependence is associated with severe medical, psychiatric, and social morbidity, but no pharmacotherapy is approved for its treatment in the United States." | 2.74 | Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees. ( Brodie, JD; Case, BG; Dewey, SL; Figueroa, E; Laska, EM; Robinson, JA; Wanderling, JA, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pan, Y | 1 |
| Gerasimov, MR | 1 |
| Kvist, T | 1 |
| Wellendorph, P | 1 |
| Madsen, KK | 1 |
| Pera, E | 1 |
| Lee, H | 1 |
| Schousboe, A | 1 |
| Chebib, M | 1 |
| Bräuner-Osborne, H | 1 |
| Craft, CM | 1 |
| Brodie, JD | 6 |
| Schiffer, WK | 2 |
| Dewey, SL | 8 |
| Miller, SR | 2 |
| Silverman, RB | 2 |
| Silverman, K | 1 |
| DeFulio, A | 1 |
| Leoutsakos, JM | 1 |
| Somoza, EC | 1 |
| Winship, D | 1 |
| Gorodetzky, CW | 1 |
| Lewis, D | 1 |
| Ciraulo, DA | 1 |
| Galloway, GP | 1 |
| Segal, SD | 1 |
| Sheehan, M | 1 |
| Roache, JD | 1 |
| Bickel, WK | 1 |
| Jasinski, D | 1 |
| Watson, DW | 1 |
| Somoza, P | 1 |
| Winhusen, T | 1 |
| Case, BG | 1 |
| Figueroa, E | 4 |
| Robinson, JA | 1 |
| Wanderling, JA | 1 |
| Laska, EM | 2 |
| Brady, KT | 1 |
| Berezina, TL | 1 |
| Khouri, AS | 2 |
| Winship, MD | 1 |
| Fechtner, RD | 2 |
| Marsteller, D | 1 |
| Filip, M | 1 |
| Frankowska, M | 1 |
| Gołda, A | 1 |
| Zaniewska, M | 1 |
| Vetulani, J | 1 |
| Przegaliński, E | 1 |
| Ramirez, M | 1 |
| Federico, M | 1 |
| Morgan, AE | 1 |
| Ashby, CR | 1 |
| Horan, B | 1 |
| Kushner, SA | 1 |
| Logan, J | 1 |
| Volkow, ND | 1 |
| Fowler, JS | 1 |
| Gardner, EL | 1 |
| Wickelgren, I | 1 |
| Stromberg, MF | 1 |
| Mackler, SA | 1 |
| Volpicelli, JR | 1 |
| O'Brien, CP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study[NCT00611130] | Phase 2 | 186 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Double-Blind, Randomized, Placebo- Controlled Trial of Vigabatrin for Short Term Abstinence From Cocaine in Cocaine Dependent Parolees[NCT00527683] | Phase 2 | 100 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of subjects in the CPP-109 Vigabatrin Group vs. Number in Placebo Group abstinent from using cocaine during Weeks 11 and 12 of the Treatment Phase. (NCT00611130)
Timeframe: Week 13
| Intervention | participants (Number) |
|---|---|
| CPP-109 Vigabatrin Tablets, 500 mg | 7 |
| Matching Placebo Tablets | 5 |
Using retained urine samples and prior to unblinding, up to 12 specimens/ subject were analyzed for vigabatrin levels. Compliance assessment based on > or = 70% of urines in subjects assigned to vigabatrin having quantitative levels of vigabatrin indicaticative of taking drug within the last 24 hours of clinic visit. (NCT00611130)
Timeframe: Week 2, 4, 6 & 9-11
| Intervention | participants (Number) | |
|---|---|---|
| Number of Vigabatrin Completers Analyzed | Number Medication Compliant | |
| Treatment Phase Completers | 61 | 24 |
6 trials available for vigabatrin and Cocaine Abuse
| Article | Year |
|---|---|
A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence.
Topics: Adult; Cocaine; Cocaine-Related Disorders; Double-Blind Method; Female; GABA Agents; Humans; Male; M | 2013 |
Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees.
Topics: Adult; Alcoholism; Anticonvulsants; Cocaine-Related Disorders; Combined Modality Therapy; Double-Bli | 2009 |
Visual field and ocular safety during short-term vigabatrin treatment in cocaine abusers.
Topics: 4-Aminobutyrate Transaminase; Adult; Aged; Cocaine-Related Disorders; Double-Blind Method; Enzyme In | 2012 |
Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA.
Topics: Adult; Cocaine-Related Disorders; Enzyme Inhibitors; Female; GABA Agents; Humans; Male; Treatment Ou | 2003 |
Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction.
Topics: Cocaine-Related Disorders; Enzyme Inhibitors; Female; Humans; Male; Methamphetamine; Substance-Relat | 2005 |
Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin: ocular safety pilot results.
Topics: Adult; Amphetamine-Related Disorders; Cocaine-Related Disorders; Enzyme Inhibitors; Female; GABA Age | 2006 |
9 other studies available for vigabatrin and Cocaine Abuse
| Article | Year |
|---|---|
(1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a potent γ-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction.
Topics: 4-Aminobutyrate Transaminase; Animals; Biological Availability; Carboxylic Acids; Cocaine-Related Di | 2012 |
The potential value of a negative finding: an illustrative example.
Topics: Cocaine-Related Disorders; Female; GABA Agents; Humans; Male; Vigabatrin | 2013 |
Expanding treatment options for cocaine dependence.
Topics: Adult; Alcoholism; Animals; Cocaine-Related Disorders; Disease Models, Animal; Drug Approval; Drug-R | 2009 |
The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms.
Topics: 4-Aminobutyrate Transaminase; Animals; Anticonvulsants; Awards and Prizes; Cocaine-Related Disorders | 2012 |
Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.
Topics: 4-Aminobutyrate Transaminase; Animals; Cocaine; Cocaine-Related Disorders; Dopamine; Dose-Response R | 2003 |
Various GABA-mimetic drugs differently affect cocaine-evoked hyperlocomotion and sensitization.
Topics: Amines; Animals; Behavior, Animal; Brain; Cocaine; Cocaine-Related Disorders; Cyclohexanecarboxylic | 2006 |
A novel strategy for the treatment of cocaine addiction.
Topics: 4-Aminobutyrate Transaminase; Animals; Brain; Catalepsy; Cocaine; Cocaine-Related Disorders; Conditi | 1998 |
Drug may suppress the craving for nicotine.
Topics: Animals; Behavior, Animal; Brain; Cocaine-Related Disorders; Conditioning, Psychological; Dopamine; | 1998 |
The effect of gamma-vinyl-GABA on the consumption of concurrently available oral cocaine and ethanol in the rat.
Topics: Alcohol Drinking; Animals; Behavior, Addictive; Cocaine; Cocaine-Related Disorders; Disease Models, | 2001 |